Alvotech stock climbs after FDA clears new Simlandi production process
Dow Jones Newswires reports Alvotech shares gained 8% to $5.41 after the FDA cleared a more productive manufacturing method for its Humira biosimilar Simlandi.
- published on Newsmetry
- original source published
the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner. connect the api →
what happened
Dow Jones Newswires reports that Alvotech's stock rose about 8% to $5.41 in early trading after the US regulator signed off on an upgraded manufacturing method for Simlandi, the company's biosimilar version of Humira.
Alvotech said the authorization lets it run its Process 2.0 for adalimumab drug substance at its facility in Reykjavik, Iceland. According to the company, the updated method more than doubles output per batch while keeping the upstream production scale unchanged.
The company credited targeted process development, a smooth technology transfer and successful validation, and stated that product quality, safety and efficacy remain comparable to the earlier approved process.
why it matters
The shares are still down 37% over the past 12 months, so the news mainly concerns the company itself rather than the wider sector. For investors, the key point is manufacturing capacity: higher output per batch could improve the economics of the biosimilar, though the report gives no estimate of any financial effect.
market impact
Alvotech: FDA approval boosts batch output for its Humira biosimilar, supportive for the company's shares
tags
instruments
sources
- Alvotech Shares Rise After FDA Okays Simlandi Manufacturing Process — Dow Jones Newswires, 20 October 2026 at 13:45 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner.
get stories in real time ↗